Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach.

[1]  Anthony K. Felts,et al.  Identification of Alternative Binding Sites for Inhibitors of HIV-1 Ribonuclease H Through Comparative Analysis of Virtual Enrichment Studies , 2011, J. Chem. Inf. Model..

[2]  P. Markt,et al.  Alizarine derivatives as new dual inhibitors of the HIV‐1 reverse transcriptase‐associated DNA polymerase and RNase H activities effective also on the RNase H activity of non‐nucleoside resistant reverse transcriptases , 2011, The FEBS journal.

[3]  Daniela Schuster,et al.  Development of anti-viral agents using molecular modeling and virtual screening techniques. , 2011, Infectious disorders drug targets.

[4]  Thomas Seidel,et al.  Strategies for 3D pharmacophore-based virtual screening. , 2010, Drug discovery today. Technologies.

[5]  Rui M. M. Brito,et al.  Toward the Discovery of Functional Transthyretin Amyloid Inhibitors: Application of Virtual Screening Methods , 2010, J. Chem. Inf. Model..

[6]  J. Bajorath,et al.  Quo vadis, virtual screening? A comprehensive survey of prospective applications. , 2010, Journal of medicinal chemistry.

[7]  R. Di Santo,et al.  HIV-1 RT-associated RNase H function inhibitors: Recent advances in drug development. , 2010, Current medicinal chemistry.

[8]  J. Bajorath,et al.  Scaffold hopping using two-dimensional fingerprints: true potential, black magic, or a hopeless endeavor? Guidelines for virtual screening. , 2010, Journal of medicinal chemistry.

[9]  Christopher L. Daniels,et al.  Structural Basis for the Inhibition of RNase H Activity of HIV-1 Reverse Transcriptase by RNase H Active Site-Directed Inhibitors , 2010, Journal of Virology.

[10]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[11]  Marie-Dominique Devignes,et al.  Comparison of Three Preprocessing Filters Efficiency in Virtual Screening: Identification of New Putative LXRβ Regulators As a Test Case , 2010, J. Chem. Inf. Model..

[12]  Gisbert Schneider,et al.  Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.

[13]  M. Radi,et al.  HIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide Substrate , 2010, Viruses.

[14]  Benjamin A. Ellingson,et al.  Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database , 2010, J. Chem. Inf. Model..

[15]  B. Roquebert,et al.  [[Au: English title missing, please check.]] , 2010 .

[16]  Ajay N. Jain,et al.  Molecular Shape and Medicinal Chemistry: A Perspective , 2010, Journal of medicinal chemistry.

[17]  Richard A. Lewis,et al.  Three-dimensional pharmacophore methods in drug discovery. , 2010, Journal of medicinal chemistry.

[18]  Dennis M. Krüger,et al.  Comparison of Structure‐ and Ligand‐Based Virtual Screening Protocols Considering Hit List Complementarity and Enrichment Factors , 2010, ChemMedChem.

[19]  A. D. Clark,et al.  Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site. , 2009, Structure.

[20]  Pekka Tiikkainen,et al.  Critical Comparison of Virtual Screening Methods against the MUV Data Set , 2009, J. Chem. Inf. Model..

[21]  Xiaohong Liu,et al.  RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. , 2009, Journal of medicinal chemistry.

[22]  Yung‐chi Cheng,et al.  Inhibition of HIV-1 ribonuclease H activity by novel frangula-emodine derivatives. , 2009, Medicinal chemistry (Shariqah (United Arab Emirates)).

[23]  E. Clercq,et al.  Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. , 2009, International journal of antimicrobial agents.

[24]  Sean Ekins,et al.  The importance of discerning shape in molecular pharmacology. , 2009, Trends in pharmacological sciences.

[25]  Simona Distinto,et al.  How To Optimize Shape-Based Virtual Screening: Choosing the Right Query and Including Chemical Information , 2009, J. Chem. Inf. Model..

[26]  N. Yamamoto,et al.  Derivatives of 5-nitro-furan-2-carboxylic acid carbamoylmethyl ester inhibit RNase H activity associated with HIV-1 reverse transcriptase. , 2009, Journal of Medicinal Chemistry.

[27]  S. Sarafianos,et al.  Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. , 2009, Journal of molecular biology.

[28]  F. Bailly,et al.  Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. , 2008, Journal of medicinal chemistry.

[29]  Hanna Geppert,et al.  Integrating Structure‐ and Ligand‐Based Virtual Screening: Comparison of Individual, Parallel, and Fused Molecular Docking and Similarity Search Calculations on Multiple Targets , 2008, ChemMedChem.

[30]  M. Wendeler,et al.  Vinylogous ureas as a novel class of inhibitors of reverse transcriptase-associated ribonuclease H activity. , 2008, ACS chemical biology.

[31]  G Wolber,et al.  Enhancing drug discovery through in silico screening: strategies to increase true positives retrieval rates. , 2008, Current medicinal chemistry.

[32]  Andrew R. Leach,et al.  A Comparison of Field‐Based Similarity Searching Methods: CatShape, FBSS, and ROCS. , 2008 .

[33]  D. Jochmans.  Novel HIV-1 reverse transcriptase inhibitors. , 2008, Virus research.

[34]  Valerie J Gillet,et al.  A Comparison of Field-Based Similarity Searching Methods: CatShape, FBSS, and ROCS , 2008, J. Chem. Inf. Model..

[35]  Robert P. Sheridan,et al.  Comparison of Topological, Shape, and Docking Methods in Virtual Screening. , 2007 .

[36]  J. Stewart.  Optimization of parameters for semiempirical methods V: Modification of NDDO approximations and application to 70 elements , 2007, Journal of molecular modeling.

[37]  Robert P. Sheridan,et al.  Comparison of Topological, Shape, and Docking Methods in Virtual Screening , 2007, J. Chem. Inf. Model..

[38]  Thierry Langer,et al.  Efficient overlay of small organic molecules using 3D pharmacophores , 2007, J. Comput. Aided Mol. Des..

[39]  P. Hawkins,et al.  Comparison of shape-matching and docking as virtual screening tools. , 2007, Journal of medicinal chemistry.

[40]  Jennifer L. Knight,et al.  HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. , 2006, ACS chemical biology.

[41]  Peter Willett,et al.  Similarity-based virtual screening using 2D fingerprints. , 2006, Drug discovery today.

[42]  Stefano Alcaro,et al.  GBPM: GRID-based pharmacophore model: concept and application studies to protein-protein recognition , 2006, Bioinform..

[43]  Hugo Kubinyi,et al.  Success Stories of Computer‐Aided Design , 2006 .

[44]  E. Tramontano.  HIV-1 RNase H: recent progress in an exciting, yet little explored, drug target. , 2006, Mini reviews in medicinal chemistry.

[45]  T. Mirzadegan,et al.  Recent progress in the design of small molecule inhibitors of HIV RNase H. , 2006, Current pharmaceutical design.

[46]  Victor Guallar,et al.  Importance of accurate charges in molecular docking: Quantum mechanical/molecular mechanical (QM/MM) approach , 2005, J. Comput. Chem..

[47]  J. Irwin,et al.  ZINC ? A Free Database of Commercially Available Compounds for Virtual Screening. , 2005 .

[48]  V. Pathak,et al.  Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[49]  R. Di Santo,et al.  6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. , 2005, Antiviral research.

[50]  M. Andreola.  Closely related antiretroviral agents as inhibitors of two HIV-1 enzymes, ribonuclease H and integrase: "killing two birds with one stone". , 2004, Current pharmaceutical design.

[51]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[52]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[53]  Hans-Joachim Böhm,et al.  A guide to drug discovery: Hit and lead generation: beyond high-throughput screening , 2003, Nature Reviews Drug Discovery.

[54]  Jürgen Bajorath,et al.  Integration of virtual and high-throughput screening , 2002, Nature Reviews Drug Discovery.

[55]  N. Sluis-Cremer,et al.  Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. , 2002, Molecular pharmacology.

[56]  N. Sluis-Cremer,et al.  Mutational Analysis of Tyr-501 of HIV-1 Reverse Transcriptase , 2002, The Journal of Biological Chemistry.

[57]  W L Jorgensen,et al.  Prediction of drug solubility from Monte Carlo simulations. , 2000, Bioorganic & medicinal chemistry letters.

[58]  Stefano Alcaro,et al.  A “quasi‐flexible” automatic docking processing for studying stereoselective recognition mechanisms. Part I. Protocol validation , 2000, J. Comput. Chem..

[59]  W. L. Jorgensen,et al.  Prediction of Properties from Simulations: Free Energies of Solvation in Hexadecane, Octanol, and Water , 2000 .

[60]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[61]  W. Clark Still,et al.  AMBER torsional parameters for the peptide backbone , 1992 .

[62]  Cheng Yung-Chi,et al.  HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587. , 1992 .

[63]  W. C. Still,et al.  Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .

[64]  G. Chang,et al.  Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .

[65]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[66]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[67]  E. Freed,et al.  Novel approaches to inhibiting HIV-1 replication. , 2010, Antiviral research.

[68]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[69]  Richard A. Friesner,et al.  A mixed quantum mechanics/molecular mechanics (QM/MM) method for large-scale modeling of chemistry in protein environments , 2000, J. Comput. Chem..

[70]  F. Gasparrini,et al.  A quasi-flexible automatic docking processing for studying stereoselective recognition mechanisms. Part I. Protocol validation , 2000, J. Comput. Chem..

[71]  S. Goff,et al.  Reverse Transcriptase and the Generation of Retroviral DNA , 1997 .

[72]  E. Tramontano,et al.  HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587. , 1992, Biochemical pharmacology.

[73]  T. Yonetani.  The Yonetani-Theorell graphical method for examining overlapping subsites of enzyme active centers. , 1982, Methods in enzymology.